Matthew Pauls was appointed Chair and Chief Executive Officer (CEO) of Savara Pharmaceuticals in December 2020 after previously having served as Chair and Interim CEO since September 2020. He has been a member of the company’s Board of Directors since April 2017. Additionally, Mr. Pauls is on the Board of Directors of Zyla Life Sciences (subsidiary) and Amplo Biotechnology, a private pre-clinical gene therapy company. With more than 25 years in the biopharmaceutical industry, Mr. Pauls brings a wealth of public company senior leadership and a successful track record as a general manager. Most recently he founded Spartan Biopharma, LLC where he provided strategic advisement to institutional investors, C-suite executives, and board directors. From 2014 through 2019, Mr. Pauls was President and Chief Executive Officer and on the Board of Directors of Strongbridge Biopharma plc (NASDAQ: SBBP), a rare disease biopharmaceutical company domiciled in Ireland, where he took the company public on the NASDAQ exchange in 2015. Mr. Pauls also previously served as Chair of the Board of Directors at Mast Therapeutics. His earlier leadership positions include Chief Commercial Officer of Insmed, Inc. and Senior Vice President, Head of Global Commercial Operations at Shire Pharmaceuticals. He has also held senior management roles at Bristol-Myers Squibb and Johnson & Johnson and holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.
Nevan Elam has served as a member of the Savara Board since February 2009. Mr. Elam is currently the President, Chief Executive Officer and Chairman of Rezolute, Inc., a biopharmaceutical company focused on developing novel extended release therapies. Prior to his tenure at AntiraBio which began in October 2012, Mr. Elam served for three years as the Chief Executive Officer and President of AeroSurgical Ltd., a medical device company operating out of Ireland. Prior to his service with AeroSurgical Ltd., Mr. Elam was Head of the Pulmonary Business Unit and Senior Vice President of Nektar Therapeutics. Earlier in his career he was a founder and Chief Financial Officer of E2open as well as a Partner in the corporate practice of the law firm of WSGR. In addition to serving on the Rezolute Board of Directors, he also serves on the Board of Directors of pH Pharmaceuticals in Seoul, Korea. Mr. Elam received his Juris Doctorate from Harvard Law School and a Bachelors of Arts from Howard University. Savara believes Mr. Elam’s broad experience with pharmaceutical companies, including advising them of their unique legal and regulatory obligations, qualifies him to serve on the Savara Board.
Richard J. Hawkins has served as a member of the Savara Board since October 2010. Since September 2010, Mr. Hawkins has served as President and Chief Executive Officer of Lumos Pharma, Inc., a clinical stage biotechnology company focused on bringing novel therapies to patients with severe, rare, and genetic diseases, whose medical needs are unmet. From 2000 to 2010, Mr. Hawkins, founded and advised numerous pharmaceutical companies including Sensus, where he served as co-founder and Chairman until being sold to Pfizer. From 1981 to 2000, Mr. Hawkins was founder, President and CEO of Pharmaco and guided the company’s growth to over 2,000 employees. The company later merged with PPD of Wilmington, NC to form PPD Pharmaco, one of the largest clinical contract research organizations in the world. Mr. Hawkins received his Bachelor of Science in Biology from Ohio University. Savara believes Mr. Hawkins’s experience in the pharmaceutical and life sciences industries as well as his broad management experience qualify him to serve on the Savara Board.
Dr. Joseph S. McCracken is Savara’s Lead Independent Director, has served as a member of the Savara Board since October 2013 and currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives. Joe also serves on the boards of several biopharmaceutical companies, including Alkahest, Inc., and Regimmune Inc. From July 2011 to September 2013, Dr. McCracken was Vice President and Global Head of Business Development & Licensing for Roche Pharma, a research-focused healthcare company, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. From October 2009 until July 2011 he was General Manager, Roche Pharma Japan & Asia Regional Head, Roche Partnering. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for more than 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate of Veterinary Medicine from The Ohio State University. Savara believes Dr. McCracken’s extensive experience in the biotechnology and pharmaceutical industries qualifies him to serve on the Savara Board.
Mr. Ramsay has served on our Board of Directors since June 2011. Mr. Ramsay retired from Halozyme Therapeutics, Inc. (NASDAQ: HALO) in July 2015, where he served as Chief Financial Officer since May 2013 and from 2003 to May 2009. He also served as Halozyme’s Vice President, Corporate Development from May 2009 to May 2013. From 2000 to 2003, Mr. Ramsay was Vice President, Chief Financial Officer of Lathian Systems, Inc., a provider of technology-based sales solutions for the life science industry. From 1998 to 2000, he was with Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.), where he served as Vice President, Treasurer and Director, Corporate Finance. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and a M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.
Ricky Sun, Ph.D., joined our Board of Directors in December 2019. He is currently a Partner at Bain Capital Life Sciences and serves on the Board of Directors of Arcutis and Annexon. Before Bain, Dr. Sun was Director of Corporate Development and Strategy at Biogen and his prior roles include Vice President at BlackRock, and senior healthcare analyst at Citadel and Alyeska Investment Group. Previously, he spent time on Wall Street as a pharmaceutical equity research analyst at Lehman Brothers and Morgan Stanley and served as a senior scientist at Ironwood Pharmaceutical. Dr. Sun received his Doctor of Philosophy degree in Chemistry and Chemical Biology from Harvard University and was an NIH postdoctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School. He also received an MBA from New York University’s Stern School of Business where he was a Mildred Elperin Scholar. Dr. Sun graduated summa cum laude from Berea College with a Bachelor of Arts degree in Chemistry.
Dr. An van Es-Johansson has served on our Board of Directors since December 2019. She is currently the Chief Medical Officer and Head of Development for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease. From 2005-2018, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Sobi, an international rare disease company headquartered in Stockholm, Sweden. Dr. van Es-Johansson has leadership experience within large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech, and BioStratum. From 2004 -2016 she was a member of the Scientific Adboard for Uppsala Bio and currently serves on the Board of Directors at BioInvent International AB, Medivir AB, PLUS Therapeutics, and Agendia BV. Dr. van Es-Johansson received a M.D. from Erasmus University, Rotterdam, The Netherlands.